Peptide Therapy Consent Form: Free Template for Clinicians

A peptide therapy consent form records that your patient understands what they are starting: which compounds, how strong the evidence is, the risks, where the drug comes from, and how to stop. Most peptides are prescribed off-label and many are compounded, so a signed form carries more weight here than for a routine prescription.

Below is a template covering the ten sections a peptide consent form needs. Copy the wording into your own form, or get the full 36-page kit as a free PDF.

Have your healthcare counsel review it before use. The template is built from what a peptide consent needs to cover, but it is not attorney-drafted and has not been checked against your state's law.

How the paperwork fits together

A peptide practice uses five documents. The patient signs three of them.

What a peptide consent form must cover

Verbal consent covers none of these. Get a signed, dated form, and record in the chart which compounds and evidence grades it covered.

Peptide therapy consent form template

The wording in each shaded box goes on the patient's form. Tips underneath are for you and stay off the patient's copy.

1. Compound identity and regulatory status

I have been told which specific compounds are being prescribed to me, and the current regulatory status of each one. I understand that the regulatory status of these compounds can change, that my prescriber verifies current status at the time of prescribing, and that a compound available to me today may not be available at my next refill.

Tip: name every compound on the form. A category name is too vague to show what the patient agreed to.

2. Off-label use

I understand that most or all of the compounds prescribed to me are being used off-label, meaning for a purpose other than the one an approval covers. Off-label prescribing is legal and common in American medicine. Roughly one in five prescriptions written in the United States is off-label, and oncologists, pediatricians, and psychiatrists rely on it routinely. The legal requirement is not that the use be on-label. It is that my prescriber has a reasonable clinical basis for the decision and has documented it.

3. Strength of the evidence

For each compound prescribed to me, my prescriber has told me the strength of the evidence supporting it, using the following grades, and has told me which grade applies to my prescription:

Category A. Strong human evidence. Robust human trial data supports the clinical effect, even where the specific use is off-label.

Category B. Moderate human evidence. Clinical literature, international use, or substantial case reports support it, but the human trial data is less complete than Category A.

Category C. Primarily mechanistic or experimental. There is a strong biological rationale and positive clinical experience, but limited rigorous human trial data for the use being prescribed. Where human data is absent entirely, I have been told that explicitly.

Tip: write the grade beside each compound. If the consent is ever examined, this section matters most, and calling Category C evidence Category A is the most damaging mistake you can make here.

4. Risks

I have been told the known risks and side effects of each compound prescribed to me, including effects that are expected and benign and effects that require me to contact the office. I have also been told the theoretical risks, meaning concerns that arise from how a compound works but that human data has not confirmed or ruled out. I understand that the absence of clear human data does not confirm safety and does not confirm harm.

Tip: risks specific to each compound class go in the class addenda in the PDF.

5. Sourcing

I understand that my compounds are prepared by a licensed 503A compounding pharmacy against a prescription written specifically for me. A 503A pharmacy compounds for individual patients; a 503B outsourcing facility produces larger batches without patient-specific prescriptions. These are physician-prescribed, physician-use-only preparations. There is no page where I can add them to a cart and check out.

I understand that products sold online by research chemical suppliers are not the same thing, are not tested for purity, potency, or sterility, and are not what I am being prescribed.

Tip: name the pharmacy in the chart. For the law behind this section, see are peptides legal?

6. Alternatives and the right to stop

I have been told the alternatives to this therapy, including conventional treatment options and the option of doing nothing. I understand that I may decline peptide therapy, and that I may stop at any time, for any reason, without affecting the rest of my care.

7. Monitoring

I have been given the monitoring plan for my protocol: which labs will be drawn, at what intervals, and what results or symptoms would prompt my prescriber to change the dose or stop the therapy. I understand that monitoring is part of the treatment and not optional.

If I have a reaction, I will stop immediately and contact the office. I understand this is what my prescriber wants me to do, and that stopping early and calling is the response that keeps harm minimal.

Tip: patients who read "stop and call" on a form they signed act on it more reliably than patients told once at the door.

8. Realistic benefit and timeline

My prescriber has told me the realistic expected benefit of this therapy and the realistic timeline over which I should expect it, not the best possible outcome. I understand that peptides are signaling molecules used to reach a specific goal. They are a tool, not a cure, and not a guaranteed result.

9. Cost

I have been told what this therapy costs, and that many peptide protocols are ongoing rather than a single course. I understand the continuing financial commitment before starting.

10. Self-injection

I understand that most peptides are injected, that I will be taught to inject myself, and that I will demonstrate the technique in the office before I take the protocol home. I understand that taking the doses on the prescribed schedule materially affects whether the therapy works.

Tip: ask about needles early in the visit. In-office injections work for a patient who cannot self-inject.

Signature

I have read this document. I have had the opportunity to ask questions and my questions have been answered. I understand that I may ask further questions at any point during treatment. I consent to the peptide therapy described to me.

Below the statement, leave lines for:

• Patient name, signature, and date
• Prescriber name, signature, and date
• The compounds and evidence grades this consent covers
• The class addenda signed with it

Off-label and compounded product disclosure

The patient signs this with the general consent. It explains in plain terms what the consent refers to. Many patients have already researched peptides online and some have bought them, so write it as an explanation rather than a warning.

What off-label prescribing is

A medication is prescribed off-label when it is used for a condition, a patient population, or a dose other than the one covered by its approval. Off-label prescribing is legal in the United States and is a normal part of medical practice. Approximately twenty percent of all prescriptions written in this country are off-label. It is routine in oncology, pediatrics, and psychiatry.

Off-label does not mean experimental, and it does not mean unsafe. It means the evidence supporting this particular use sits outside the label, and my prescriber is required to have a reasonable clinical basis for the decision and to document it. I have been told the evidence grade for each compound I am being prescribed.

What a compounding pharmacy is

My compounds are prepared by a licensed 503A compounding pharmacy. A 503A pharmacy prepares medications for individual patients against a prescription written for that patient by name. This is different from a commercially manufactured, FDA-approved product that arrives in a sealed manufacturer's package.

A 503B outsourcing facility is a different category that produces larger batches without patient-specific prescriptions. My prescription is being filled through the 503A pathway.

Licensed compounding pharmacies test for purity, potency, and sterility.

Why sourcing elsewhere is different

Peptides sold online by research chemical suppliers, often labeled "not for human consumption," are not tested to the same standard and in many cases are not tested at all. Independent testing has found endotoxin contamination in approximately eight percent of grey market samples. Some samples contained none of the compound named on the label.

I understand that my prescriber cannot vouch for, monitor, or manage the risks of any product I obtain outside the prescribed pathway, and that using one alongside a prescribed protocol makes it impossible to tell what caused any effect I experience, good or bad.

Tip: if the patient has already used grey market peptides, note it in the chart. It changes how you read an early reaction.

Regulatory changes

The regulatory status of compounded peptides in the United States is actively changing. A compound available to me today may become unavailable, and a compound unavailable today may become available. My prescriber verifies the current status of each compound at the time it is prescribed. I understand that a protocol may have to change for regulatory reasons rather than clinical ones.

The disclosure gets its own signature lines, plus a line for the compounding pharmacy named in the chart.

Before you use it

1. Send it to your counsel. States add their own rules: witnessed signatures, required wording for compounded drugs, telehealth exams, and out-of-state pharmacy licensing.
2. Check regulatory status before each new patient. Status changes, so reconfirm any form printed more than three months ago. Our legality guide is updated when FDA acts.
3. Pair the signature with a teach-back. The patient injects in front of you before taking anything home.
4. Confirm your prescribing scope. A consent form does not extend anyone's authority to prescribe. See who can prescribe peptides by license and state.

The consent conversation, evidence grading, and the class addenda are taught in full in Peptavo's accredited peptide therapy course, which carries AMA PRA Category 1 credit.

Frequently asked questions

Do I need a written consent form for peptide therapy?

Yes. Most peptides are prescribed off-label and many are compounded, and verbal consent is not enough for off-label compounded prescribing. A signed, dated form that names each compound and its evidence grade documents what the patient agreed to.

Can I use this peptide consent form as written?

Use it as a draft. It is a starting point for any state, built from what a peptide consent needs to cover, and it has not been reviewed against any state's law. Have your healthcare counsel adapt it before a patient signs it.

Do patients sign a separate consent for each peptide?

No. They sign the general consent and the off-label disclosure once, then one addendum per compound class. A patient on two peptides from the same class signs one addendum; a patient on peptides from two classes signs two.

Does the consent form need a witness?

That depends on your state. Some states require witnessed signatures for certain consents, so ask your counsel whether to add a witness line.